MANGOCEUTICALS, INC. 8-K

What Happened

• On February 19, 2026, Mangoceuticals, Inc. (the “Company”) filed a Form 8-K (Item 7.01) and issued a press release reporting the initial results of sales for its newly launched all‑inclusive injectable testosterone replacement therapy (TRT) treatment program. The press release is furnished as Exhibit 99.1 to the Form 8-K.
• The filing also includes customary disclosures about forward‑looking statements and the Company’s statement that it will not update those statements except as required by law.

Key Details

• Filing date: February 19, 2026 (Form 8-K, Item 7.01).
• Topic: initial sales results of the Company’s newly launched all‑inclusive injectable TRT treatment program.
• Press release included as Exhibit 99.1 to the Current Report on Form 8-K.
• The filing contains forward‑looking statement disclaimers noting risks and uncertainties and directing investors to the Company’s SEC filings for more information.

Why It Matters

• The announcement signals the Company has moved from product launch to initial commercial sales, a key operational milestone that could affect future revenue if traction continues.
• Because the 8-K reports initial sales results but does not provide detailed financial metrics in the filing itself, investors should watch for follow‑up disclosures (e.g., quarterly reports, additional press releases) for concrete revenue, volume, or margin data.
• The use of Regulation FD disclosure means the information was made public to all investors simultaneously; investors should consider the filing in the context of Mangoceuticals’ broader SEC filings and risk disclosures.